Sep. 4 at 1:25 PM
$HURA Great questions. One key difference is that IFx-2.0 does not require tumor sequencing, computational neoantigen selection and patient-specific manufacturing in the way intismeran does. Rather than predicting which neoantigens should be targeted, IFx-2.0 is designed to work in situ and expose the patient’s immune cells to the neoantigens present in the tumor itself.
There is also a potential difference in antigen breadth. Intismeran is built around a selected set of neoantigens, while IFx-2.0 is designed to allow the immune system to process the neoantigens present across the tumor, potentially supporting a broader spectrum of antigen recognition.
